AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02164864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran Etexilate 110mg
Description: Active treatment
Study NCT02164864 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin 3mg
Description: Active comparator
Study NCT02164864 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Active comparator
Study NCT02164864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran Etexilate 150mg
Description: Active treatment
Study NCT02164864 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel or Ticagrelor
Description: Active comparator
Study NCT02164864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel or Ticagrelor
Description: Active comparator
Study NCT02164864 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin 5mg
Description: Active comparator
Study NCT02164864 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin 1mg
Description: Active comparator
Study NCT01803763 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omalizumab (Xolair)
Description: Fixed dose of 300 mg omalizumab is subcutaneously administered in total 4 monthly doses
Study NCT01803763 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Fixed dose of placebo is subcutaneously administered in total 4 monthly doses
Study NCT01187901 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erlotinib
Description: Tarceva oral tablets are conventional, immediate-release tablets containing erlotinib as the hydrochloride salt. Erlotinib(75mg)will be taken once daily for six months in combination with sulindac.
Study NCT01187901 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulindac
Description: Sulindac is a non-steroidal, anti-inflammatory indene derivative designed for the treatment of arthritic conditions. For this study, sulindac (150mg) will be taken twice daily in combination with erlotinib
Study NCT01187901 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo A
Description: Erlotinib (Tarceva) will provide a 25 mg identical placebo. This will be provided by the Division of Cancer Prevention at the NIH who will receive the drug and placebo from the manufacturer, OSI/Genentech. Dosage for Placebo A will be 75 mg a day for 6 months.
Study NCT01187901 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo B
Description: Sulindac will be encapsulated in 150 mg doses along with an identical encapsulated Placebo B. One 150 mg capsules of Placebo B will be taken twice per day with meals (breakfast and supper).
Study NCT02231658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Study NCT02231658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lixisenatide
Study NCT02871180 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Late night snack
Description: The late night snack was one slice of whole meal rye bread containing approximately 20 g of carbohydrate.
Study NCT02871180 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No late night snack
Description: Patient consumed no nutrients at late night.
Study NCT00930124 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Orthognathic surgery
Description: Patients with moderate maxillary hypoplasia needing an advancement of 4-10mm
Study NCT00930124 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Distraction osteogenesis
Study NCT03243461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide + Valproic Acid
Description: Valproic acid additionally to simultaneous radiochemotherapy with temozolomide
Study NCT03781063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasofoxifene
Description: Estrogen receptor antagonist antineoplastic agent
Study NCT03781063 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: Estrogen receptor antagonist antineoplastic agent
Study NCT05323968 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Abdominal Ultrasonography
Description: The result of the Abdominal Ultrasonography will be compared with that of the Abdominal Computerized Tomography
Study NCT05323968 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Abdominal Computerized Tomography
Description: The result of the Abdominal Computerized Tomography will be compared with that of the Abdominal Ultrasonography
Study NCT00444886 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin Type A injection (BOTOX)
Description: Each subject will receive an injection under EMG guidance into the anterior and middle scalene muscles of either 75 units of BTX-A (experimental group), or normal saline (control group). Both groups will be provided with a stretching and strengthening exercise program.
Study NCT00004285 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard dose, low flux hemodialysis
Study NCT00004285 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard dose, high flux hemodialysis
Study NCT00004285 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High dose, low flux hemodialysis
Study NCT00004285 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High dose, high flux hemodialysis
Study NCT02954003 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endo Bypass System
Description: Subject is implanted with the device for up to 3 years.
Study NCT00147732 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Accelerated radiotherapy
Description: 68 Gy over 5.5 weeks
Study NCT00147732 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: ARCON
Description: 68 Gy over 5.5 weeks Carbogen: 98% oxygen plus 2% carbon dioxide Nicotinamide 60 mg/kg daily
Study NCT02514460 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: plaque excision system
Study NCT02514460 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stent
Study NCT01784406 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Autonomy supportive counselling
Study NCT01750398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone cypionate
Description: DEPO-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble of the androgenic hormone testosterone. Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. DEPO-Testosterone Injection is available in two strengths, 100 mg/mL and 200 mg/mL testosterone cypionate.
Study NCT01750398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin
Description: Goserelin is a hormone therapy, for intramuscular injectionis. It is classified as an LHRH agonist.
Study NCT01750398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide
Description: Leuprolide is a gonadotropin-releasing hormone (GnRH) agonist. For intramuscular injection.
Study NCT03129178 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Concentrated beetroot juice
Description: Acute and chronic supplementation of beetroot juice.
Study NCT01912768 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FID 120947A contact lens disinfecting solution
Description: Investigational 3% hydrogen peroxide solution intended for simultaneous cleaning, protein removal, disinfecting and storage of silicone hydrogel and soft contact lenses
Study NCT01912768 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: renu fresh multi-purpose solution
Description: Commercially available solution indicated for cleaning, removing protein deposits, rinsing, chemical disinfection, and storage of soft contact lenses
Study NCT01912768 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soft contact lenses
Description: Commercially available soft contact lenses worn a minimum of 8 hours each day on a daily wear basis for the duration of the study (90 days). A fresh pair will be dispensed on Day 0, Day 30, and Day 60.
Study NCT01912768 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Soft contact lenses
Description: Commercially available soft contact lenses worn a minimum of 8 hours each day on a daily wear basis for the duration of the study (90 days). A fresh pair will be dispensed on Day 0, Day 30, and Day 60.
Study NCT00894413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: 20 mg once daily for 10 - 14 days
Study NCT00894413 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Pill
Description: Placebo
Study NCT00511407 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renal tubule assist device
Description: Standard hemofiltration cartridge containing nonautologous human renal tubule cells, connected to conventional continuous venovenous hemodialysis circuit.
Study NCT01375504 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Counseling
Description: The control group will receive two sessions of dietary counseling (with instruction to follow a weight loss program) provided by a clinical dietician, consistent with current routine care for adults with obesity.
Study NCT01375504 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mindfulness Training Program
Description: The mindfulness program will be administered over three 90-minute sessions by a physician and clinical dietician with expertise in mind-body medicine and nutrition.
Study NCT00978861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrogen Peroxide
Description: Whitening product syringe type
Study NCT01817387 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PRIME
Description: Mobile application designed to improve psychosocial functioning and motivational deficits
Study NCT01817387 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: Auditory processing, verbal learning, memory, processing speed, and social cognition
Study NCT01121159 — intervention group
Intervention type: PROCEDURE
Intervention: orbital fracture repair
Description: All patients will receive orbital fracture repair with one of the 4 specified implants
Study NCT02810262 — intervention group
Intervention type: OTHER
Intervention: Bone metastases biopsy
Description: The vast majority of bone biopsy are performed under CT-scan. In some rare cases, the histology will be performed during surgery (either biopsy of the bone metastasis or surgical piece when treating a fracture).
Study NCT03691402 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MCT-Silver
Description: Metacognitive training for depression in later life (MCT-Silver) is a cognitive-behaviorally based group therapy, which focuses on helping participants gain (metacognitive) distance from their thought patterns that contribute to depression. Over 8 modules, MCT-Silver addresses issues specific to depression in later life, such as coping with physical changes and loss, as well as adapting to new (social) roles. The program also includes modules on identifying and re-defining values in later life and how one may move toward acceptance of situations that cannot be prevented or changed. MCT-Silver addresses cognitive and metacognitive biases that contribute to the onset and maintenance of depression through fun and engaging exercises, as well as using examples from daily life.
Study NCT03691402 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Remediation
Description: mybraintraining© is a computer-based cognitive remediation program, which covers a wide range of neuropsychological exercises involving memory, reasoning, selective attention and psychomotor speed. The program is administered individually on personal computers and each session lasts approximately 45-60 min. To match the MCT-Silver group, participants will complete up to eight sessions of cognitive remediation.
Study NCT01150955 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Resveratrol
Description: 500 mg three times a day for five weeks.
Study NCT01150955 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (starch capsules) 500 mg three times a day for five weeks.
Study NCT03453151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: splanchnic nerve anesthesia with a local anesthetic
Description: regional nerve block with a local anesthetic (Lidocaine/Bupivacaine)
Study NCT03334162 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sensorimotor training
Description: Supervised training sessions will last for about 20 to 30 minutes in total, including a child-specific warm-up and cool-down. The children will be asked to maintain balance in a previously acquired short-foot-position, knees slightly flexed (30°), without shoes. Training will consist of 5 playful balance exercises, chosen from a standardized pool of exercises according to the child's age, with increasing difficulty (5 degrees of difficulty - e.g. by reducing the base of support, or dual task exercises - per exercise depending on the age group) in order to allow for individual, optimal progression. Each of the 5 exercises will contain of 5 repetitions for 10sec. allowing for a 20sec. rest in between each set and a 1min rest between each exercise in order to avoid neural fatigue. Children will be given a training manual and diary to train at home after the study. Guardians will be instructed in order to be able to assist their children
Study NCT04265586 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Sleep hygiene education is either face-to-face appointment or video-meeting with trained nurse.
Study NCT04265586 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based Cognitive Behavioural Therapy (iCBT)
Description: iCBT is a web-based programme (7-16 weeks) designed to treat the symptoms of insomnia.
Study NCT00636376 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Place HOB in alternate positions from 0-50 degrees.
Description: Patients will receive an US while the HOB(Elevation of the head of bed) is 30 degrees(baseline) then they will increase the angle to 40 degrees, then 50 degrees. Another US will be done then in 20, 10, and o degree angles. Then another US will be done
Study NCT02266901 — intervention group
Intervention type: PROCEDURE
Intervention: endoscopic drainage
Description: Endoscopic percutaneous access was obtained through surgical drains or after ultrasound-guided percutaneous drainage with a thin scope , and transluminal procedures with large scopes through the leak hole. All the procedures were performed under general anesthesia and carbon dioxide insufflation. Debridement was done by pus aspiration and irrigation.
Study NCT01822041 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARN-509
Description: Single oral dose of 240 mg ARN-509
Study NCT02102009 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Complete enteral formula
Description: Product: Complete nutritional formula in powder enriched with key nutrients to be administered orally (200 ml of water per 57 g product).~Time of intervention: 3 months.
Study NCT02102009 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Advise
Description: Patients will receive the usual dietary advise in these patients according hospital clinical practice .
Study NCT04782921 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xenogenic bone graft material
Description: After access to the periodontal defect via straight incision in vestibulum, at the mucogingival border or short releasing incision on adjacent tooth, Gel 40 (a mixture of collagen gel and xenogenic bone particles) or Gen-Os (pure xenogenic bone particles) will be inserted.
Study NCT04782921 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Xenogenic bone graft material
Description: After access to the periodontal defect via straight incision in vestibulum, at the mucogingival border or short releasing incision on adjacent tooth, Gel 40 (a mixture of collagen gel and xenogenic bone particles) or Gen-Os (pure xenogenic bone particles) will be inserted.
Study NCT02434081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is a fully human monoclonal antibody that targets the programmed death-1 (PD-1) cell surface membrane receptor. PD-1 is a negative regulatory molecule expressed by activated T and B lymphocytes.Binding of PD-1 to its ligands, 1 (PD-L1) and 2 (PD-L2), results in the down-regulation of lymphocyte activation. Nivolumab inhibits the interaction of programmed cell death Protein 1 (PD-1)with its ligands, PD-L1 and PD-L2, resulting in enhanced T-cell proliferation.
Study NCT00725985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Cladribine tablets were administered until CDMS conversion, whichever occur first.
Study NCT03203889 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CRAFT-AI
Description: Community Reinforcement Approach and Family Training (CRAFT) uses principles of operant conditioning to help a concerned significant other improve their own psychological functioning and influence the identified person with addiction to seek help
Study NCT03203889 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TSF-CSO
Description: In individual sessions, the counselor facilitates the CSO's affiliation and involvement in Nar-Anon or Al-Anon groups to work the steps.
Study NCT00509639 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 10% Metronidazole Ointment
Description: Metronidazole 10% ointment applied perianally three times daily for four weeks. Placebo ointment applied perianally three times daily for four weeks
Study NCT04962074 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microfluidic sperm sorting chip
Description: Fertile Ultimate® (Koek Biotechnology, Turkey) microfluidic sperm sorting chips
Study NCT04962074 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Density gradient
Description: Density gradient centrifugation
Study NCT02786732 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 210mg Brodalumab
Description: Brodalumab 210mg administered subcutaneously
Study NCT02786732 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: 210mg Brodalumab
Description: Brodalumab 210mg administered subcutaneously
Study NCT02786732 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 140mg Brodalumab
Description: Brodalumab 140mg administered subcutaneously
Study NCT02786732 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Ustekinumab
Description: Ustekinumab 45mg or 90mg adminstered subcutaneously
Study NCT00725985 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to cladribine tablets were administered.
Study NCT00725985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matched to cladribine tablets were administered.
Study NCT00739973 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02786732 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered subcutaneously
Study NCT03741894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iodoform
Description: Patients get iodoform (1000 grams containing 350 grams of iodoform, 300 grams of glycerin and 350 grams of alcohol 96%) soaked gauze (steril selvedge gauze bandage 2 cm x 5 m in appropriate length) drainage during suture placements for a week.
Study NCT03741894 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wound closure using sutures
Description: Routine primary wound closure with single interrupted sutures (Surgilon 3-0 non-absorbable) only.
Study NCT00739973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren 150 mg tablet
Study NCT03741894 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Wound closure using sutures
Description: Routine primary wound closure with single interrupted sutures (Surgilon 3-0 non-absorbable) only.
Study NCT03741894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Description: Extraction sockets are filled with 1% chlorhexidine gel (Curasept ADS310, Sager Pharma, Sager Dental Kft.,Budapest, Hungary) before suture (Surgilon 3-0 non-absorbable) placements.
Study NCT02215993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel
Description: After 8 to 6 hours after the dose of 300mg and 600mg respectively. Patients will be randomized in a 1:1 ratio to receive ticagrelor the dose of 180mg and maintained dose of 90 mg twice a day for thirty days or prasugrel dose of 60mg and maintained for thirty days at a daily dose of 10mg.
Study NCT02215993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: After 8 to 6 hours after the dose of 300mg and 600mg respectively. Patients will be randomized in a 1:1 ratio to receive ticagrelor the dose of 180mg and maintained dose of 90 mg twice a day for thirty days or prasugrel dose of 60mg and maintained for thirty days at a daily dose of 10mg.
Study NCT00400829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eribulin mesylate
Description: Given IV
Study NCT03468699 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Autologous BMMC transplantation
Description: Stem cell transplantation
Study NCT03750032 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stapler appendectomy
Description: The patients randomised for this intervention will undergo stapler appendectomy.